The clinical trial you cited comprised 36% of patients with cytogenetic / adverse risk (see appendix A) whereas CHMs trial will likely be skewed to adverse risk patients.
Dr Maiti in his Zoom presentation on CHMs ADVENT AML trial said he wanted to primarily focus on adverse risk patients. He mentioned the CR rate for SoC was between 45-60% for specific cohorts and he was aiming to improve on that by 15-20% . He also wants to increase the deep remission rate (40-50%) and long term cure rate (15%) by a further 15-20%. Refer to the video at ~35min mark in Appendix B.
appendix A - study cited by JohnDPrent
appendix B - zoom video with Dr Maiti https://us02web.zoom.us/rec/play/hgnowgzV_4EgPDOyraezpUlGSdG62sEqLDeiTgnQTgBYwvso2X3lJpuZP-ovk6TMUoKupoVcVhR0O1pa.hV_3-4JjjVhU3HUr?accessLevel=meeting&hasValidToken=false&canPlayFromShare=true&from=share_recording_detail&continueMode=true&componentName=rec-play&originRequestUrl=https://us02web.zoom.us/rec/share/p2Ok1KXI0VvrSeMPC3_jCwJionNWfVr8FWrh-tw_7qr_M6jcnkXQBhOp8i0p61S3.CNlw3hWXUlYcfbbc
CHM Price at posting:
0.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)